Anticoagulation in COVID-19: not strong ...
Document type :
Compte-rendu et recension critique d'ouvrage
Title :
Anticoagulation in COVID-19: not strong for too long?
Author(s) :
Tacquard, Charles [Auteur]
Nouvel Hôpital Civil de Strasbourg
Mansour, Alexandre [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Centre d'Investigation Clinique [Rennes] [CIC]
Godon, Alexandre [Auteur]
BrainTech Laboratory [CHU Grenoble Alpes - Inserm U1205] [Brain Tech Lab ]
Gruel, Yves [Auteur]
CHU Trousseau [Tours]
Susen, Sophie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Godier, Anne [Auteur]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Albaladejo, Pierre [Auteur]
Nouvel Hôpital Civil de Strasbourg
Mansour, Alexandre [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Centre d'Investigation Clinique [Rennes] [CIC]
Godon, Alexandre [Auteur]
BrainTech Laboratory [CHU Grenoble Alpes - Inserm U1205] [Brain Tech Lab ]
Gruel, Yves [Auteur]
CHU Trousseau [Tours]
Susen, Sophie [Auteur]

Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Godier, Anne [Auteur]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Albaladejo, Pierre [Auteur]
Journal title :
Anaesthesia Critical Care & Pain Medicine
Pages :
100857
Publisher :
Elsevier Masson
Publication date :
2021-04
ISSN :
2352-5568
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Several randomised controlled trials are currently underway to evaluate the value of increasing the dose of prophylactic anticoagulation in critically ill COVID-19 patients, either at an intermediate or therapeutic dose, ...
Show more >Several randomised controlled trials are currently underway to evaluate the value of increasing the dose of prophylactic anticoagulation in critically ill COVID-19 patients, either at an intermediate or therapeutic dose, in order to decrease thrombotic complications, organ failure and possibly reduce mortality in these patients.Show less >
Show more >Several randomised controlled trials are currently underway to evaluate the value of increasing the dose of prophylactic anticoagulation in critically ill COVID-19 patients, either at an intermediate or therapeutic dose, in order to decrease thrombotic complications, organ failure and possibly reduce mortality in these patients.Show less >
Language :
Anglais
Popular science :
Non
Source :
Files
- document
- Open access
- Access the document
- Anticoagulation%20in%20COVID.pdf
- Open access
- Access the document